VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma

References

• KumarSKRajkumarSVDispenzieriAImproved survival in multiple myeloma and the impact of novel therapiesBlood2009111525162520
   Google Scholar
• SchaapveldMVisserOSieslingSSchaarCGZweegmanSVellengaEImproved survival amount younger but not among older patients with multiple myeloma in the Netherlands, a population based study since 1989Eur J Cancer Oxf England2010461160169
   PubMed Web of Science ®Google Scholar
• PulteDGondosABrennerHImprovement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER dataOncologist201116111600160321968047
   PubMed Web of Science ®Google Scholar
• TuressonIVelezRKristinssonSYLandgrenOPatterns of improved survival in patient with multiple myeloma in the 21st century: a population based studyJ Clin Oncol201028583083420038719
   PubMed Web of Science ®Google Scholar
• BrennerHGondosAPulteDRecent major improvements in long-term survival of younger patients with multiple myelomaBlood200811152521252617901246
   PubMed Web of Science ®Google Scholar
• PozziSMarcheselliLBarASurvival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a populated based analysisBr J Haematol20131631404623889344
   PubMed Web of Science ®Google Scholar
• KumarSKDispenzieriALacyMQContinued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsLeukemia20142851122112824157580
   PubMed Web of Science ®Google Scholar
• AunerHWSzydloRHoekJTrends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly pateints in recent yearsBone Marrow Transplant201550220921525387088
   PubMed Web of Science ®Google Scholar
• BarlogieBAttalMCrowleyJLong-term follow-up of autotransplantation trial for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group and University of Arkansas for Medical SciencesJ Clin Oncol20102871209121420085933
   PubMed Web of Science ®Google Scholar
• BarlogieBMitchellAvan RheeFEpsteinJMorganGJCrowleyJCuring myeloma at last: defining criteria and providing the evidenceBlood2014124203043305125293776
   PubMed Web of Science ®Google Scholar
• PalumboACavalloFGayFAutology transplantation and maintenance therapy in multiple myelomaN Engl J Med20143711089590525184862
   PubMed Web of Science ®Google Scholar
• ShahNCallanderNGangulySHematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow TransplantationBiol Blood Marrow Transplant20152171155116625769794
   PubMed Web of Science ®Google Scholar
• GertzMADingliDHow we manage autologous stem cell transplantation for patients with multiple myelomaBlood2014124688289024973360
   PubMed Web of Science ®Google Scholar
• BladéJRosiñolLCibeiraMTRoviraMCarrerasEHematopoietic stem cell transplantation for multiple myeloma beyond 2010Blood2010115183655366320203260
   PubMed Web of Science ®Google Scholar
• BarlogieBHallRZanderADickeKAlexanianRHigh-dose melphalan with autologous bone marrow transplantation for multiple myelomaBlood1986675129813013516252
   PubMed Web of Science ®Google Scholar
• AttalMHarousseauJLStoppaAMA prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myelomaN Engl J Med1996335291978649495
   PubMed Web of Science ®Google Scholar
• LahuertaJJMateosMVMartinez-LopezJBusulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 studyHaematologica201095111913192020663944
   PubMed Web of Science ®Google Scholar
• MoreauPFacotTAttalMComparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Inter-groupe Francophone du Myelome 9502 randomized trialBlood200299373173511806971
   PubMed Web of Science ®Google Scholar
• Vela-OjedaJGarcia-Ruiz-EsparzaMAPadilla-GonzalesYAutologous peripheral blood stem cell transplantation in multiple myeloma using oral versus IV melphalanAnn Hematol200786427782817262193
   PubMedGoogle Scholar
• FenkRSchneiderPKropffMHigh-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patient with multiple myeloma: results of a randomized studyBr J Haematol2005130458859416098074
   PubMed Web of Science ®Google Scholar
• PalumboABringhenSBrunoBMelphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 studyBlood2010115101873187919965659
   PubMed Web of Science ®Google Scholar
• GiraltSBensingerWGoodmanM166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trialsBlood200310272684269112730103
   PubMed Web of Science ®Google Scholar
• DesikanKRTricotGDhodapkarMMelaphalan plus total body irraditation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alongBone Marrow Transplant200025548348710713623
   PubMedGoogle Scholar
• DonatoMLAlemanAChamplinREHigh-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myelomaLeuk Lymphoma200445475575915160952
   PubMed Web of Science ®Google Scholar
• ShimoniASmithTLAlemanAThiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myelomaBone Marrow Transplant200127882182811477439
   PubMedGoogle Scholar
• San MiguelJFSchlagRKhuagevaNKBortezomib plus melphalan and prednisone for initial treatment of multiple myelomaN Engl J Med2008359990691718753647
   PubMed Web of Science ®Google Scholar
• MitsiadesNMitsiadesCSRichardsonPGThe proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsBlood200310162377238012424198
   PubMed Web of Science ®Google Scholar
• JasielecJKJakubowiakAJCurrent approaches to the initial treatment of symptomatic multiple myelomaInt J Hematol Oncol2013216170
   Google Scholar
• MoreauPAttalMFaconTFrontline therapy of multiple myelomaBlood2015125203076308425838345
   PubMed Web of Science ®Google Scholar
• RosiñolLOriolATeruelAISuperiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM studyBlood201212081589159622791289
   PubMed Web of Science ®Google Scholar
• CavoMPantaniLPetrucciMTBortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myelomaBlood2012120191922498745
   PubMed Web of Science ®Google Scholar
• MoreauPAvet-LoiseauHFaconTBortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myelomaBlood2011118225752575821849487
   PubMed Web of Science ®Google Scholar
• Gourzones-DmitrievCKassambaraASahotaSDNA repair pathways in human multiple myelomaCell Cycle201312172760277323966156
   PubMed Web of Science ®Google Scholar
• YardeDNOliveiraVMathewsLTargeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myelomaCancer Res200969249367937519934314
   PubMedGoogle Scholar
• LinYCShunCTWuMSChenCCA novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaBClin Cancer Res200612237165717317145842
   PubMedGoogle Scholar
• MitsiadesNMitsiadesCSPoulakiVApoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implicationsBlood200299124525453012036884
   PubMed Web of Science ®Google Scholar
• LandowskiTHOlashawNEAgrawalDDaltonWSCell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cellsOncogene200322162417242112717418
   PubMed Web of Science ®Google Scholar
• ReskeTFulcinitiMMunshiNCMechanism of action of immunomodulatory agents in multiple myelomaMed Oncol201027Suppl 1S7S1320405248
   PubMed Web of Science ®Google Scholar
• HideshimaTChauhanDShimaYThalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapyBlood20009692943295011049970
   PubMed Web of Science ®Google Scholar
• WangXSShiQShahNDInflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantationClin Cancer Res20142051366137424423611
   PubMedGoogle Scholar
• YangWCLinSFMechanisms of drug resistance in relapse and refractory multiple myelomaBiomed Res Int2015201534143026649299
   PubMed Web of Science ®Google Scholar
• IshikawaHTanakaHIwatoKEffect of glucocorticoids on the biologic activities of myeloma cells: inhibition of interleukin-1 beta osteoclast activating factor-induced bone resorptionBlood19907537157202297574
   PubMedGoogle Scholar
• DurieBGHarousseauJLMiguelJSInternational uniform response criteria for multiple myelomaLeukemia20062091467147316855634
   PubMed Web of Science ®Google Scholar
• PaivaBvan DongenJJMOrfaoANew criteria for response assessment: role of minimal residual disease in multiple myelomaBlood2015125203059306825838346
   PubMed Web of Science ®Google Scholar
• PalumboAAvet-LoiseauHOlivaSRevised international staging system for multiple myeloma: a report from International Myeloma Working GroupJ Clin Oncol201533262863286926240224
   PubMed Web of Science ®Google Scholar
• KorthalsMSehnkeNKronenwettRMolecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myelomaBiol Blood Marrow Transplant20131971109111523644045
   PubMedGoogle Scholar
• RawstronACOrfaoABeksacMReport of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disordersHaematologica200893343143818268286
   PubMedGoogle Scholar
• MohtyMHarousseauJLTreatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answersHaematologica201499340841624598852
   PubMedGoogle Scholar
• UsmaniSZCrowleyJHoeringAImprovement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?Leukemia201327122623222705990
   PubMed Web of Science ®Google Scholar
• PalumboAAvontoIBrunoBIntermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myelomaClin Lymphoma Myeloma20066647547716796778
   PubMedGoogle Scholar
• GilLStyczynskiJKomarnickiMInfectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factor analysis and outcomeInfection2007256421427
   Google Scholar
• JonesJAQazilbashMHShihYCCantorSBCooksleyCDEltingLSIn-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malagnanciesCancer200811251096110518286506
   PubMed Web of Science ®Google Scholar
• VesoleDHBarlogieBJagannathSHigh-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplantsBlood19948439509567913845
   PubMedGoogle Scholar
• JagannathSVesoleDHGlennLCrowleyJBarlogieBLow-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell supportBlood1992807166616721391937
   PubMedGoogle Scholar
• BarlogieBKyleRAAndersonKCStandard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US intergroup trial S9321J Clin Oncol200624692993616432076
   PubMed Web of Science ®Google Scholar
• ShahDPGhantojiSSMulanovichVEAriza-HerediaEJChemalyRFManagement of respiratory viral infections in hematopoietic cell transplant recipientsAm J Blood Res20122420321823226621
   PubMedGoogle Scholar
• WinnANShahGLCohenJTLinPJParsonsSKThe real world effectiveness of hematopoietic transplant amount elderly individuals with multiple myelomaJ Natl Cancer Inst20151078 pii:djv139
   PubMedGoogle Scholar
• KumarSKDingliDLacyMQAutologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysisAm J Hematol200883861461718429054
   PubMed Web of Science ®Google Scholar
• ShahGLWinnANPinPJCost-effectiveness of autologous hematopoietic stem cell transplantation in elderly patients with multiple myeloma using surveillance, epidemiology and end results-Medicare databaseBiol Blood Marrow Transplant201521101823182926033281
   PubMed Web of Science ®Google Scholar
• KapoorPKumarSKDispenzieriAImportance of achieving stringent complete response after autologous stem-cell transplantation in multiple myelomaJ Clin Oncol201331364529453524248686
   PubMed Web of Science ®Google Scholar
• Martinez-LopezJPaivaBLopez-AngladaLCritical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonalityBlood2015126785886226089396
   PubMed Web of Science ®Google Scholar
• Coustan-SmithESanchoJHancockMLClinical importance of minimal residual disease in childhood acute lymphoblastic leukemiaBlood20009682691269611023499
   PubMedGoogle Scholar
• van DongenJJvan der VeldenVHBrüggemannMOrfaoAMinimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologiesBlood2015125263996400925999452
   PubMed Web of Science ®Google Scholar
• CampanaDMinimal residual disease in acute lymphoblastic leukemiaASH Educ Program Book201020101712
   Google Scholar
• PaivaBVidrialesM-BCerveróJMultiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantationBlood2008112104017402318669875
   PubMed Web of Science ®Google Scholar
• RawstronACChildJAde TuteRMMinimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX StudyJ Clin Oncol201331202540254723733781
   PubMed Web of Science ®Google Scholar
• Martinez-LopezJLahuertaJJPepinFPrognostic value of deep sequencing method for minimal residual disease detection in multiple myelomaBlood2014123203073307924646471
   PubMed Web of Science ®Google Scholar
• RousselMLauwers-CancesVRobillardNFront-line transplantation program with lenalidomide, bortezomib and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du MyelomeJ Clin Oncol201432252712271725024076
   PubMed Web of Science ®Google Scholar
• Jimenez-ZepedaVHDugganPNeriPBortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplantLeuk Lymphoma201657497397626450458
   PubMed Web of Science ®Google Scholar
• PaivaBCorcheteLAVidrialesMBPhenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistanceBlood20161271518961906326755711
   PubMed Web of Science ®Google Scholar